Milgram Laura J H
Division of Pediatric Pulmonology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Ann Am Thorac Soc. 2014 Jul;11(6):975-9. doi: 10.1513/AnnalsATS.201403-129AR.
The United States Food and Drug Administration recently considered a policy to transfer inhaled short-acting bronchodilators to over-the-counter status if conditions of safe use can be established. The American Thoracic Society filed a comment in opposition to the proposal. This article examines the negative consequences that might result from allowing nonprescription access to bronchodilators and other inhaled asthma medications. Such a proposed policy change conflicts directly with current guidelines for asthma management and would undermine efforts to achieve adequate asthma control in patients. In addition, a policy change to convert asthma medications to over-the-counter status could result in increased costs to patients as well as increased health care costs to society overall due to a worsening of asthma control in the population.
美国食品药品监督管理局最近考虑一项政策，即如果能够确定安全使用条件，就将吸入性短效支气管扩张剂转为非处方药。美国胸科学会提交了一份反对该提议的意见。本文探讨了允许非处方获取支气管扩张剂和其他吸入性哮喘药物可能产生的负面后果。这样一项提议的政策变化与当前的哮喘管理指南直接冲突，会破坏在患者中实现充分哮喘控制的努力。此外，将哮喘药物转为非处方药的政策变化可能会给患者带来更高的成本，同时由于人群中哮喘控制情况恶化，还会导致社会整体医疗保健成本增加。
